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Abstract
Matrix metalloproteinase (MMP)-7, unlike many MMPs, is typically expressed
in epithelial cells. It has been linked to epithelial responses to infection, injury,
and tissue remodeling including the progression of a number of cancers. We
have now examined how MMP-7 expression changes in the progression to
esophageal adenocarcinoma (EAC), and have studied mechanisms regulating
its expression and its functional significance. Immunohistochemistry revealed
that MMP-7 was weakly expressed in normal squamous epithelium adjacent
to EAC but was abundant in epithelial cells in both preneoplastic lesions of
Barrett’s esophagus and EAC particularly at the invasive front. In the stroma,
putative myofibroblasts expressing MMP-7 were abundant at the invasive
front but were scarce or absent in adjacent tissue. Western blot and ELISA
revealed high constitutive secretion of proMMP-7 in an EAC cell line (OE33)
that was inhibited by the phosphatidylinositol (PI) 3-kinase inhibitor
LY294002 but not by inhibitors of protein kinase C, or MAP kinase activation.
There was detectable proMMP-7 in cultured esophageal myofibroblasts but it
was undetectable in media. Possible metabolism of MMP-7 by myofibroblasts
studied by proteomic analysis indicated degradation via extensive endopepti-
dase, followed by amino- and carboxpeptidase, cleavages. Myofibroblasts
exhibited increased migration and invasion in response to conditioned media
from OE33 cells that was reduced by MMP-7 knockdown and immunoneu-
tralization. Thus, MMP‑7 expression increases at the invasive front in EAC
which may be partly attributable to activation of PI 3-kinase. Secreted MMP-7
may modify the tumor microenvironment by stimulating stromal cell migra-
tion and invasion.
Introduction
The gastrointestinal epithelium undergoes continuous
remodeling to maintain tissue architecture both in the
face of normal cell proliferation and differentiation, and
as part of the adaptive responses following infection or
injury. The matrix metalloproteinases (MMPs) are zinc-
dependent proteases that constitute one class of extra-
cellular matrix (ECM) proteolytic enzyme that,
collectively, are involved in maintaining and remodeling
the ECM, and the cell attachments to it (Sternlicht and
Werb 2001). These events are crucial for the orderly cell
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migration and invasion that underpin the maintenance of
epithelial organization. Importantly, however, they are
disrupted in the progression to major epithelial diseases
including cancer where they participate in events central
to the process of metastasis (Egeblad and Werb 2002;
Gialeli et al. 2011).
The incidence of esophageal adenocarcinoma (EAC)
has increased markedly in the past few decades (Pohl and
Welch 2005; Zhang 2013). The most important risk factor
is Barrett’s esophagus (BE) which is characterized by
intestinal metaplasia (IM) of the esophagus attributable
to reflux of gastric acid and bile salts (Lagergren et al.
1999; Spechler and Souza 2014). The overall rate of pro-
gression from BE to EAC is relatively low with estimates
of less than 0.5% of BE individuals developing EAC per
annum; however, progression is increased in patients with
low-grade dysplasia (LGD) and substantially so in patients
with high-grade dysplasia (HGD) (Desai et al. 2012; Duits
et al. 2015). The mechanisms that determine progression
of this disease are therefore of considerable importance in
developing targeted strategies for the identification, moni-
toring, and treatment of those patients most at risk of
progression to EAC.
Matrix metalloproteinase (MMP)-7 (also known as
matrilysin or PUMP) is distinctive in that it is the
smallest MMP and is predominantly expressed in epithe-
lial cells (Wilson and Matrisian 1996). It has been linked
to tissue responses to infection in the small intestine
(Wilson et al. 1999), mucosal remodeling in the stom-
ach in response to gastrin and H.pylori (McCaig et al.
2006; Varro et al. 2007), and in the progression of a
number of epithelial cancers including stomach, pan-
creas, colon, and breast as well as esophagus (McDon-
nell et al. 1991; Adachi et al. 1998; Salmela et al. 2001;
Crawford et al. 2002, 2003; Vargo-Gogola et al. 2002).
However, the mechanisms regulating expression are
incompletely explored. In the stomach, there is evidence
that the pyloric antral hormone gastrin regulates expres-
sion (Varro et al. 2007) and it is interesting therefore
that cholecystokinin-2 receptors (CCK2R), at which
gastrin acts, are expressed in BE (Haigh et al. 2003;
Lee et al. 2017). The present study was undertaken to
evaluate the pattern of expression of MMP‑7 in EAC,
the mechanisms regulating its expression in an EAC cell
line, and its functional significance in influencing stro-
mal cell migration and invasion.
Materials and Methods
Patients
Paraffin embedded tissue of surgically resected tumors,
and adjacent BE or macroscopically normal tissue, from
patients with EAC (n = 14, 9 male; 70  3 years), and of
endoscopic biopsies from patients with BE IM (n = 17,
12 male; 66  3 years), low-grade dysplasia (n = 17, 14
male; 65  3 years) or high-grade dysplasia (n = 12, 8
male; 66  3) were taken from the Biobank of the
Pathology Department of the University of Szeged.
Histopathology was assessed by an experienced gastroin-
testinal pathologist using the Vienna classification (Sch-
lemper et al. 2000; Grin and Streutker 2014). Staging of
the tumors by the TNM system (Sobin et al. 2009) indi-
cated that most were invasive, that is pT3 (pT1, 2/14;
pT2, 3/14; pT3, 9/14), most exhibited no or low lymph
node involvement, that is pN0 (6/14) or pN1 (6/14; pN2,
1/14, pN3, 1/14), and most were not metastatic, that is
M0 (13/14; M1, 1/14). In addition, biopsies were taken
for mRNA extraction from 45 patients (64  2 years; 36
male) with BE IM verified by histopathology (n = 33, IM;
n = 8, both IM and cardiac/fundic metaplasia; n = 2, IM
and low-grade dysplasia; n = 2, IM and adenocarcinoma)
attending for routine endoscopic surveillance at the Gas-
trointestinal Units of the Royal Liverpool University
Hospital or the First Department of Medicine of the
University of Szeged. All patients gave informed consent
and the studies were approved by the NHS Regional
Ethics Committee or the University of Szeged ethics com-
mittee.
Cells
The EAC and gastroesophageal junction cancer cell lines,
OE33 and OE19, respectively, were obtained from Ameri-
can Type Culture Collection (Manassas, VA, USA);
OE33-Gr cells, expressing CCK2R, have previously been
described (Haigh et al. 2003). Three cancer-associated
myofibroblast (CAM) lines generated from tumors of
patients with EAC were used; these were prepared using
methods previously described (Holmberg et al. 2012; Bal-
abanova et al. 2014; Kumar et al. 2014). An earlier study
showed these cells to differ in their miRNA profiles from
gastric cancer and to a lesser extent squamous cell eso-
phageal cancer myofibroblasts (Wang et al. 2016).
Drugs and hormones
Human unsulfated heptadecapeptide gastrin (hG17) was
obtained from Bachem (St Helens, Merseyside, UK).
Human progastrin was a generous gift from Prof T.C.
Wang (Columbia University, New York, USA), Gly-
extended gastrin-17 (G17-gly) and C-terminal flanking
peptide extended gastrin (G17-CFP) were purchased from
Pepsyn (Liverpool, Lancs, UK); brefeldin A (BFA), Ro32-
04332, U0126 and LY294002 were obtained from Merck
Millipore (Watford, Herts, UK). Other reagents were
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purchased from Sigma Aldrich (Poole, Dorset, UK) unless
otherwise stated.
Immunohistochemistry
Formalin-fixed paraffin embedded sections were processed
for immunohistochemistry using antigen retrieval and
stained with mouse monoclonal antibody to human
MMP‑7 (Merck Millipore) as previously described
(Wroblewski et al. 2003; Kumar et al. 2015). Stromal and
epithelial compartments in 10 high power fields of repre-
sentative sections were scored separately for staining
intensity on a four-point scale (0–3) by two independent
pathologists and the percentage of stained epithelial or
spindle-shaped stromal cells at each intensity were
recorded.
Immunocytochemistry
Cultured cells were processed for immunocytochemistry
using primary rabbit antibody to CCK2R (Atlas, Stock-
holm, Sweden) and mouse monoclonal antibody to
MMP-7 and the appropriate fluorescein labelled sec-
ondary antibody raised in donkey (Jackson Immunore-
search, Soham, Cambs, UK), and mounted with
Vectashield containing DAPI (Vector Laboratories,
Peterborough, Cambs, UK) as previously described
(Kumar et al. 2014).
Calcium imaging
OE33-Gr cells were loaded with 2 lmol/L Fluo-4 AM
(Invitrogen, Paisley, Renfrewshire, UK), and stimulated
with hG17 (10 nmol/L) and with ionomycin (1 lmol/L)
as a positive control as described previously (Pennington
et al. 2007; Simpson 2013).
ELISA
Rabbit polyclonal antibodies were generated to the N-
terminal 15 residues of MMP-7 (YSLFPNSPKWTSKVVC-
amide, corresponding to [Cys110]-preproMMP-7 95-110)
conjugated to keyhole limpet haemocyanin using m-mal-
eimidobenzoyl-N-hydroxysuccinimide ester through the
C-terminal Cys attached for the purpose (Cambridge
Research Biochemicals, Billingham, Cleveland, UK). Anti-
bodies were screened by indirect ELISA using the original
antigenic peptide and L522 was selected for further analy-
sis based on titer and specificity. An indirect ELISA was
generated using Maxisorp (Thermo Scientific, Loughbor-
ough, UK) 96-well plates, with 100 mmol/L carbonate
buffer pH 9.6 for coating (2 h, on a shaker); wash buffer
was 0.05% Tween-20 in 0.02mol/L sodium barbitone
buffer pH 8.4 and blocking buffer contained 1% BSA.
Standards and samples were diluted in Plasma Sample
Diluent (Bio-Rad, Kidlington, Oxon, UK). Antibody L522
was used at 1:5000 (overnight, 4°C on a shaker). The sec-
ondary antibody was biotinylated anti-rabbit IgG (Sigma
Aldrich) at 1:20,000 (2 h) followed by high sensitivity
streptavidin-HRP (Thermo Scientific) at 1:20,000 and
using 3,30,5,50 tetramethylbenzidine Supersensitive (Sigma
Aldrich) as a substrate. The ELISA exhibited parallel dilu-
tion of OE33 cell extracts and media with standard
recombinant human MMP-7; the ELISA reacted with
both MMP-7 and proMMP-7 as well as with N-terminal
fragments of MMP-7 (95-110 and 97-108 of preproMMP-
7) but not with peptides corresponding to sequences
C-terminal to this region (102-113, 114-125, 134-145).
Inter-assay variation was 9.1% and intra-assay variation
was 7.4%; the limit of detection was 0.015pM.
Western blot
Media was concentrated using StrataClean resin (Agilent
Technologies, Santa Clara, CA, USA) and cell extracts
were prepared in RIPA buffer containing protease and
phosphatase inhibitors (Merck Millipore)(Holmberg et al.
2012). Samples were resolved by SDS-PAGE electrophore-
sis and processed for western blotting using antibodies to
MMP-7 (L522), MMP-1 (R & D Systems), phospho- and
total Akt (Cell Signaling Technology, Danvers, MA, USA).
Cell extracts were reprobed for GAPDH (Biodesign, Saco,
Maine, USA) to normalize for protein loading.
Proteomic studies
Myofibroblasts were plated at 1 9 106 cells in 10 cm
dishes and grown for 24 h in full media. Cells were then
washed three times with PBS, and cultured in serum-free
medium for 1 h. The medium was discarded and replaced
with 5 mL serum-free medium with or without MMP-7
(2 lg/mL). Medium was collected after 30 min or 24 h
and centrifuged at 800g for 7 min. StrataClean was added
to media (10 lL/mL), mixed for 1 min, centrifuged and
washed three times with 25 mmol/L ammonium bicar-
bonate. StrataClean-bound protein samples were resus-
pended in 25 mmol/L ammonium bicarbonate and
denatured by addition of 0.05% (w/v) RapiGest (Waters)
and incubated at 80°C for 10 min. Samples were then
reduced by 3 mmol/L DTT at 60°C for 10 min, alkylated
by 9 mmol/L iodoacetamide for 30 min (ambient temper-
ature in the dark) and digested by addition of sequenc-
ing-grade trypsin in a roughly 50:1 protein:trypsin ratio
(37°C, 18 h). Digested peptides were collected in a fresh
tube by centrifugation at 14,000g for 10 min, followed by
a further elution with 50 lL 0.5mol/L NaCl. Samples
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were then desalted using C18 ZipTips (Millipore), dried,
and resuspended in 20 lL 3% acetonitrile, 0.1% formic
acid. Samples were analysed on a Nano-Acquity (Waters)
reverse phase HPLC system in-line with an LTQ Orbitrap
Velos (Thermo).
To investigate proteolytic cleavage of MMP7, raw data
files were imported into PEAKs v.8 (Bioinformatics Solu-
tions Inc, ON, Canada) and de novo peptide sequence-
directed peak searches performed. PEAKs database
searches against the Uniprot human reviewed database
were carried out with no defined protease specified. Car-
bamidomethyl cysteine was specified as a fixed modifica-
tion and oxidation of methionine as a variable
modification with a precursor mass tolerance of 10 ppm
and fragment ion tolerance of 0.5 Da. The data was
adjusted to a peptide false discovery rate of 1%.
Raw LC-MS files were processed using Progenesis-QI
v.2.0 (Waters Ltd, Newcastle-upon-Tyne, UK) to deter-
mine relative protein abundance. All raw files were ini-
tially automatically aligned, according to retention time,
to produce an aggregate LC-MS map, from which peptide
feature charge states +1 and >+7 were excluded. Data
were then separated into two experimental groups (1)
30 min MMP7 (3 biological replicates) and (2) 24 h
MMP7 (3 biological replicates). An aggregate peak list file
(mgf format) was then searched against the human
reviewed UniProt database using the Mascot search
engine (v. 2.4.1, Matrix Science, UK Relative protein
quantification was based on averaging the individual
abundances of 5 unique tryptic peptides identified for
MMP7 in each sample.
MMP-7 knockdown
OE33 cells were transfected using AmaxaTM V cell line
NucleofectorTM kit (Amaxa; K€oln, Germany) with silenc-
ing RNA (siRNA) for MMP-7 and scrambled controls
(Sigma-Aldrich) using nucleofection as previously
described (Kumar et al. 2014). Control and MMP-7
knockdown cells (106 cells per flask) were then taken and
further incubated for 24 h in SF medium. Conditioned
medium (CM) was collected, centrifuged and stored at
80°C for migration and invasion assays.
Cell migration and invasion assays
Transwell migration and invasion assays of myofibroblasts
and OE33 cells were performed using 8 lm pore size BD
inserts and BD BioCoatTM MatrigelTM invasion chambers
as appropriate (BD Bioscience, Oxford, UK)(Holmberg
et al. 2012). Undiluted OE33 cell CM with or without
MMP-7 knockdown was placed in the well. Migrating/in-
vading cells were fixed, stained with Quick-Diff (Reagena,
Toivala, Finland) and counted in five fields per mem-
brane with experiments performed in triplicate. In addi-
tion, immunoneutralization using a mouse monoclonal
anti-human MMP-7 (1:200; R & D Systems) was
employed to study CAM migration in response to OE33
CM.
Radioimmunoassay
Serum gastrin was determined by radioimmunoassay
using antibody to the C-terminus of G17 which reacts
equally with G17 and G34, but not with progastrin or
C-terminal variants of G17 (Dockray et al. 1991).
qPCR
Biopsies were extracted and RNA reverse transcribed
using Promega AMV RT reagents (Kumar et al. 2015).
Multiplex real time qPCR was performed using an
Applied Biosystems AB7500 system with manufacturer
supplied software ver2.3. The following Taqman primer/
probe pairs were employed: GAPDH: 50-GCT CCT CCT
GTT CGA CAG TCA-30(forward), 50-ACC TTC CCC
ATG GTG TCT GA-30 (reverse), 50-CGT CGC CAG CCG
AGC CAC A-30 (probe); MMP-7: 50-GGA TGG TAG
CAG TCT AGG GAT TAA CT-30 (forward), 50-GGA ATG
TCC CAT ACC CAA AGA A-30 (reverse), 50-CCT GTA
TGC TGC AAC TCA TGA ACT TGG C-30 (probe);
CCK2R: 50-TGA CTC TGG GAT GCT CCT AGT-30 (for-
ward), 50-TGG TCA GAG GTA TGA GAT TAG GC-30
(reverse), 50-ACC TCA CAG TGA CCC TTC CCA ATC
AGC-30 (probe). Results were expressed as DCT normal-
ized to GAPDH.
Statistics
Data are expressed as mean  SE and comparisons were
made by ANOVA or t test as appropriate.
Results
Increased expression of MMP-7 in the
progression to cancer
In normal tissue adjacent to EAC tumors, MMP-7 was
expressed in <50% of squamous epithelial cells and the
staining intensity was relatively low (Fig. 1A). In contrast,
in Barrett’s lesions adjacent to tumors there was expres-
sion in a majority of epithelial cells (78  4% cells scored
1)(Fig. 1B); moreover, MMP-7 was localized to the
majority of cells in dysplastic and EAC lesions(Fig. 1C
and D). For the purposes of this study, we made a dis-
tinction between staining in the body of the tumor
2018 | Vol. 6 | Iss. 10 | e13683
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(80  3% cells scored at least 2 for intensity) and at the
invasive front where over 90% scored at the highest
intensity (Fig. 1D and E). Unexpectedly, in stroma puta-
tive myofibroblasts (identified as spindle-shaped cells)
were identified that expressed MMP-7; these were scarce
or absent in tissue adjacent to cancer, were present in low
abundance in dysplastic regions (Fig. 1F), were com-
moner in the body of the tumor (Fig. 1G) and were most
abundant at the invasive front (75  7% cells scored 3)
(Fig. 1H).
We further examined expression of MMP-7 in biopsies
taken from BE patients exhibiting IM, LGD or HGD
(Fig. 2A–C). Expression of MMP-7 was found in virtually
all epithelial cells and was at the highest intensity in
HGD. In general, stromal cells were sparse in biopsies
and the sample size was considered inadequate for an
assessment of MMP-7 in these cells.
Constitutive expression of MMP-7 in OE33
cells
To study in more detail the cellular basis of MMP-7 pro-
duction we first compared the EAC and gastroesophageal
junction cell lines OE33 and OE19, respectively, for expres-
sion and secretion using western blot and ELISA. A band
corresponding to proMMP-7 was detectable in low
abundance in OE19 cells but was undetectable in media; in
contrast, in OE33 cells there was high abundance of
proMMP-7 in both cells and media and there was a minor
band corresponding to mature MMP-7 (Fig. 3A). Since BE
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Figure 1. Expression of MMP-7 in EAC and preneoplastic tissue. (A) epithelial cells in control squamous tissue (n = 9); (B) epithelial cells in
Barrett’s metaplasia (n = 8); (C) epithelial cells in dysplasia (n = 11); (D) epithelial cells in EAC (n = 14); (E) epithelial cells at the invasive front in
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cells express CCK2R and gastrin stimulates MMP-7 expres-
sion in the stomach (Haigh et al. 2003; Varro et al. 2007)
we then examined the effect of hG17 in OE33-Gr cells that
express CCK2R (Fig. 3B). However, in the presence of
hG17 there was no change in proMMP-7 in the media of
OE33-Gr cells (Fig. 3C). Similarly, secretion was
unchanged after stimulation of protein kinase C (which is
downstream of CCK2R) using phorbol 12-myristate 13-
acetate (PMA, 100 nmol/L)(Fig. 3A) in a concentration
that increased proMMP-1 and proMMP-3 abundance in
media (not shown). Nevertheless, proof of the functionality
of the receptor was established by showing increased intra-
cellular calcium in response to hG17 (Fig. 3D). Various
other forms of gastrin, for example, Gly-extended gastrins
have been reported to act on BE cells (Ogunwobi and
Beales 2008; Beales and Ogunwobi 2009) but in the present
study G17-Gly, progastrin or G17-CFP did not influence
proMMP-7 in OE33 cell media (Fig. 3E and F). The data
suggest that there is high constitutive secretion of
proMMP-7 in OE33 cells.
In order to determine whether the insensitivity to gastrin
seen in in vitro studies might have relevance in vivo, we
examined MMP-7 transcript abundance by qPCR in BE
biopsies from patients with serum gastrin concentrations
ranging from 6 to 495pM. There was no evidence of a cor-
relation between MMP-7 transcript abundance and serum
gastrin concentration in this group of patients (Spearman
rank correlation: P = 0.89, 43 degrees of freedom, q: -0.02).
The expression of CCK2R transcripts in the same samples
was verified and interestingly there was an inverse correla-
tion between DCT for CCK2R normalized to GAPDH
versus serum gastrin using a Spearman rank test
(P = 0.045, 43 degrees of freedom, q: 0.300).
Expression of proMMP-7 in OE33 cells
depends on PI 3-kinase
The release of proMMP-7 into the media by OE33 cells
was shown to require integrity of the secretory pathway
since it was blocked by brefeldin A (Fig. 4A and B). How-
ever, inhibitors of both protein kinase C (Ro32-0432) and
p42/44 MAP-kinase activation (U0126) had only a small
effect on proMMP-7 in the medium indicating that secre-
tion was unlikely to be attributable to drive from these
signaling pathways (Fig 4A,B); at the concentrations used,
Ro32,0432 and U0126 have been shown to virtually abol-
ish the MMP-1 response to PMA (Kumar et al. 2015).
Interestingly, an inhibitor of phosphatidylinositol-3-kinase
(PI 3-kinase)(LY294002) decreased the abundance of
proMMP-7 in medium detected by western blot (Fig. 4A)
and also by ELISA (Fig 4B); it also decreased abundance
in cell extracts (Fig. 4C). The effect of LY294002 in sup-
pressing PI 3-kinase in OE33 cells was verified by demon-
strating inhibition of phosphorylation of the downstream
target, Akt (Fig. 4C). The data suggest, therefore, that
constitutive activation of PI 3-kinase is at least partly
responsible for the high relative abundance of proMMP-7
in OE33 cells and media.
Expression of proMMP-7 but not secretion
in myofibroblasts
To examine in more detail the expression of MMP-7 in
myofibroblasts we screened three different esophageal
adenocarcinoma-derived CAMs. Cell extracts of all three
CAM lines contained detectable proMMP-7 (Fig. 5A) and
IHC indicated punctate staining of MMP-7 as expected
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for a secretory protein (Fig. 5B). Moreover, treatment of
CAMs with BFA to arrest progression along the secretory
pathway produced an increase in intracellular proMMP-7
(Fig. 5C). However, unlike OE33 cells we were unable to
detect proMMP-7 in the media of myofibroblasts
although there was abundant MMP-1 in media which was
used as a positive control (Fig. 5D). On the basis of
ELISA data, we estimate that concentrations of proMMP-
7 activity in media equate to secretion of less than
0.25 pmol per 106 myofibroblasts in 24 h compared with
5–10 pmol per 106 OE33 cells in 24 h.
Proteomic studies show degradation of
MMP-7 by myofibroblasts
We considered the possibility that myofibroblasts might
rapidly metabolize MMP-7. The metabolism of MMP-7 has
not been well-studied previously, but we found by western
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not influence proMMP-7 abundance in OE33-Gr cells or media. (D) Left, representative fluorescence images of OE33-Gr cells (top, control),
treated with G17 (10 nmol/L, center), or ionomycin (bottom); right, traces from four cells, two responded to G17 (10 nmol/L, applied at I) and
all responded to ionomycin (applied at II). (E) Gly-extended G17 (G17-Gly, 1 and 10 nmol/L) had no effect on proMMP-7 abundance in media
or cells of OE33 cells. (F) G17 extended to include the C-terminal flanking peptide of progastrin (G17-CFP, 1 and 10 nmol/L) and intact
progastrin had no effect on proMMP-7 abundance in OE33 media or cells.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
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blot that after 30 min incubation of MMP-7 with myofi-
broblasts there remained intact MMP-7 as well as minor
bands corresponding to cleavage products of 11 and
14 kDa (Fig. 6A). Quantification of MMP-7 from the
abundance of 5 unique tryptic peptides indicated abundant
protein at 30 min, but almost complete loss after 24 h
incubation (Fig. 6B). We reasoned that cleavage products
of MMP-7 would appear as semi-tryptic peptides after the
usual processing of samples by tryptic digestion. Following
incubation of myofibroblasts with MMP-7 for 30 min, we
then identified 98–130 (mean 113, in three replicates) semi-
or non-tryptic fragments of MMP-7 which on alignment
indicated endopeptidase cleavages particularly in the region
175-217 (numbering from the initiator Met in pre-
proMMP-7), followed by carboxy- and aminopeptidase
trimming of the cleavage products (Fig 6C). The data are
compatible with progressive endopeptidase cleavage of
MMP-7 by myofibroblasts followed by extensive carboxy-
and aminopeptidase trimming of the products.
Functional significance of MMP7 expression
in OE33 cells
Because MMP-7 is implicated in the remodeling of the
microenvironment elsewhere in the upper gastrointestinal
tract (e.g., stomach) (McCaig et al. 2006) we asked
whether there might be analogous functions in EAC. In
initial studies, we found recombinant human MMP-7 had
a modest effect in stimulating migration and invasion of
OE33 cells by 1.8 and 1.5 fold, respectively. However,
there was an approximately twofold stimulation of myofi-
broblast migration and a substantial 4-5 fold stimulation
of invasion in Boyden chamber chemotaxis assays
(Fig. 7A). We then measured migration and invasion of
EAC myofibroblasts in Boyden chambers in response to
OE33 cell CM either with or without knockdown of
MMP-7 expression by siRNA. Western blot confirmed
that following siRNA treatment there was an 80% reduc-
tion in proMMP-7 in OE33 media, but not MMP-1 run
as a control (Fig. 7B). The OE33 cell CM significantly
increased both migration and invasion of EAC CAMs but
following MMP-7 knockdown there was a significant
reduction in cell migration in response to CM, and a
smaller reduction in invasion (Fig. 7C and D); similar
results were obtained with migration of a second EAC
CAM line using OE33 cell CM with or without siRNA
knockdown. Moreover, OE33 CM stimulated migration
of a third EAC CAM and this was inhibited by MMP-7
immunoneutralization (CM: 1.8  0.2 fold increase in
migration over control, vs. 1.0  0.12 fold after
immunoneutralization). Interestingly, OE33 CM also
increased proliferation of myofibroblasts in serum-free
medium, but the knockdown of MMP-7 had no effect on
proliferation in these experiments (Fig. 7D).
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Figure 4. Role of PI 3-kinase in MMP-7 expression in OE33 cells. (A) Western blot showing suppression of proMMP-7 in media of OE33 cells
following treatment with brefeldin A (BFA, 10 lg/mL) and LY294002 (LY, 50 lmol/L) but not Ro32-0432 (Ro, 2 lmol/L) or UO126 (UO,
10 lmol/L). (B) Similar data obtained using an ELISA for MMP-7 in media. (C) Inhibition of PI 3-kinase with LY294002 suppressed
phosphorylation (p-, phospho; t-, total) of the downstream mediator Akt in cell extracts. In each case, experiments were performed in serum-
free medium added together with relevant drugs at the start of the experiment, the duration of the experiment was 6 h. Horizontal bars,
P < 0.05.
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Discussion
This study shows expression of MMP‑7 is associated with
the progressive epithelial changes that characterize the
transformation of normal squamous epithelium through
the preneoplastic condition of BE to EAC. Its expression
is highest at the invasive front in EAC where it is also
expressed in stromal spindle-shaped cells. Although gas-
trin regulates MMP-7 expression in stomach and CCK2
receptors are expressed in BE, we found no evidence that
gastrin is associated with increased MMP-7 in the pro-
gression to EAC. At least in an EAC cell line, we found
high constitutive expression of proMMP-7 was partly
attributable to activation of PI 3-kinase. There was some
expression of proMMP-7 in cultured myofibroblasts as
indicated by immunocytochemistry, western blot and
ELISA of cell extracts, but we were unable to detect its
presence in myofibroblast medium. However, the result
of studies of myofibroblast migration and invasion in
response to MMP-7 secreted by epithelial cells raises the
possibility that MMP-7 plays a role in the epithelial-
mesenchymal signaling that underpins the stromal cell
reorganization characteristic of EAC.
There are two main types of esophageal cancer: EAC
which predominates in western societies and squamous
esophageal cancer which occurs in high incidence in Asia.
There have been a number of studies of MMP-7 in squa-
mous esophageal cancer but MMP-7 has been less well
studied in EAC and BE (Adachi et al. 1998; Yamashita
et al. 2000; Tanioka et al. 2003; Miao et al. 2015). Sal-
mela et al., showed by in situ hybridization that MMP-7
was abundantly expressed in epithelial cells in EAC
whereas other MMPs (MMP-1, MMP-8) were less widely
expressed and TIMP-1 and -3 exhibited predominantly
stromal expression (Salmela et al. 2001). Our data suggest
relatively low expression in normal squamous esophageal
epithelium and progressively increased expression in BE,
LGD, HGD, and EAC with high expression at the invasive
front where both cancer and stromal cells express MMP-
7. A previous study using in situ hybridization noted
proMMP-7
OE33    CAM-1   CAM-2  CAM-3A B
GAPDH 50 μm 10 μm
proMMP-7
OE33   CAM-1 CAM-2 CAM-3
DOE33   CAM   CAM
BFA     – – +
proMMP-7
C
MMP-1GAPDH
Figure 5. Expression of MMP-7 in myofibroblasts. (A) In cell extracts of three different CAM lines (CAM-1, -2 and -3) there was a band
corresponding to proMMP-7 (28 kD) in western blots; in some cases, and in OE33 cells run as a positive control, there was a minor band at 26
kD. (B) Immunocytochemistry of MMP-7 in myofibroblasts revealed expression (green) in a high proportion of cells (left), and at a higher power
(right) localization is confirmed to vesicular organelles. (C) In cell extracts of myofibroblasts treated with BFA to arrest secretion there was an
increase in intracellular proMMP-7. (D) However, in the media of three different CAM lines proMMP-7 or related proteins were undetectable,
although in the same experiments there was abundant proMMP-7 in OE33 cell media run as a positive control, and there was abundant MMP-
1 in both CAM and OE33 cell media.
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MMP-7 expression in epithelial cells, while it was nor-
mally absent in stromal cells. The difference in detecting
in MMP-7 in stromal cells by immunohistochemistry
compared with in situ hybridization (Salmela et al. 2001)
may conceivably reflect different sensitivities of the two
methods. Regardless of the functional significance of
MMP-7 in EAC myofibroblasts we suggest that its pattern
of expression may provide a useful marker of invasive
activity in these tumors.
Because myofibroblasts play important roles in defining
the cancer microenvironment and cancer progression we
examined the biology of MMP-7 in myofibroblasts in
more detail. We screened three different EAC myofibrob-
last lines and found evidence of expression in cell extracts
but no evidence of presence in the medium. The localiza-
tion of MMP-7 activity to vesicles and the increased
abundance after BFA treatment are compatible with the
idea that proMMP-7 is localized to the secretory pathway.
It is conceivable that following secretion by myofibrob-
lasts there was rapid degradation to fragments that were
undetectable by the antibody (N-terminal specific) used
for western blot and ELISA. Because relatively little is
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Figure 6. Proteolysis of MMP-7 by myofibroblasts. (A) In the medium of myofibroblasts incubated (37°C, 30 min) with recombinant human
MMP-7 (2 lg), western blot reveals both the starting material (19 kD, see control samples of MMP-7 incubated in medium in the absence of
cells, ‘Control’) and two bands corresponding to degradation products at 14 and 11 kD. (B) Label-free quantification of MMP-7 in the medium,
based on the summed intensity of 5 unique tryptic peptides shows substantial loss of protein by 24 h compared with 30 min. (C) Analysis of
MMP-7 fragments after 30 min incubation revealed numerous fragments attributable to endopeptidase cleavage followed by aminopeptidase
or carboxypeptidase trimming of the cleavage products, separately or in concert; blue, tryptic peptides; red, semi-tryptic on the N-terminal side
of Lys or Arg; green, semi-tryptic on the C-terminal side of Lys or Arg; black, non-tryptic peptides. Inset is a schematic representation of the
distribution and relative abundance of cleavage products averaged over three biological replicates using Peptigram (Manguy et al. 2017). For
each residue, a green bar is drawn if this position is covered by at least one peptide in the sample; height of the bars is proportional to the
count of peptides overlapping this position; colour intensity is proportional to the summed ion intensities of peptides overlapping this position,
with dark green indicating high peptide intensity and light green indicating low peptide intensity. No fragments are observed before residue 95
which is the start of the mature form of MMP-7 used in this study.
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known of MMP-7 metabolism in any tissue, we under-
took proteomic studies to determine the pattern of cleav-
age of recombinant MMP-7 by myofibroblasts. The data
suggest endopeptidase cleavage of MMP-7 particularly in
the mid- and C-terminal part of the protein in myofi-
broblast medium followed by amino- and carboxypepti-
dase trimming of the products. At 30 min of incubation
of MMP-7 with myofibroblasts there were minor bands
seen on western blots that were in reasonable agreement
with predicted N-terminal fragments of MMP-7 following
endopeptidase cleavage (9.5 and 13.5 kD). We suggest
that the low abundance of MMP-7 in myofibroblast med-
ium is likely to be attributable both to low rates of secre-
tion and an extensive capacity for degradation. In the
future it will be useful to repeat these studies using
recombinant proMMP-7.
It has been known for some time that CCK2R, at
which the antral hormone gastrin acts, is expressed in BE
and quite recently CCK2R has been localized to a LGR5+
stem cell population (Haigh et al. 2003; Lee et al. 2017).
Barrett’s esophagus patients are typically treated with pro-
ton pump inhibitors to suppress acid secretion; however,
inhibition of acid secretion also removes an inhibitory
effect of acid on the G-cell leading to increased circulating
gastrin (Lamberts et al. 1993). Because gastrin stimulates
MMP-7 expression in stomach (Varro et al. 2007) we
hypothesized that it had similar effects in BE and EAC.
Using cells expressing the CCK2R (i.e., OE33-Gr cells) we
were readily able to confirm receptor expression and
demonstrate the capacity of cells to respond to gastrin by
an increase in intracellular calcium. However, gastrin had
no effect on MMP-7 expression, neither did stimulation
of protein kinase C (which is a downstream mediator of
CCK2R) using PMA. The so-called non-classical gastrins
(Gly-Gastrin, G17-CFP and progastrin) that have been
ascribed roles in cancer progression, including EAC, were
also inactive (Dockray 2004; Ogunwobi and Beales 2008;
Beales and Ogunwobi 2009). Moreover, we found no evi-
dence that MMP-7 transcript abundance in BE biopsies
varied with serum gastrin. Unexpectedly, however, we
found an inverse relationship between CCK2R abundance
and increasing serum gastrin concentrations. The latter
data therefore suggest a previously unsuspected auto-
regulation of CCK2R expression in BE and raise the
possibility that the effects of elevated circulating gastrin
are offset by decreased CCK2R expression. Thus, we
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suggest that mechanisms other than increased serum gas-
trin are responsible for the increased MMP-7 that occurs
in BE and EAC.
Activation of both the MAPkinase and PI 3-kinase
pathways has been described in BE and EAC together
with evidence of a link to increased cell proliferation and
expression of proteins involved in migration and invasion
including MMPs (Vona-Davis et al. 2005; Phillips et al.
2006; Keld et al. 2010; Saeed et al. 2016). A role for the
MAPkinase pathway has also previously been reported for
stimulation of MMP-1 expression in OE33 cells (Keld
et al. 2010). However, in our studies an inhibitor of p42/
44 MAPkinase activation did not supress MMP-7 expres-
sion. In the case of the PI 3-kinase pathway, the down-
stream mediator Akt is present in its activated
(phosphorylated) state in BE, dysplasia and EAC (Beales
et al. 2007) and it is known that OE33 cells over-express
Akt while the PI 3-kinase inhibitor LY294002 suppressed
stimulated proliferation (Beales et al. 2007; Pal et al.
2012). The present data indicate that LY294002 also sig-
nificantly reduced the abundance of proMMP-7 in med-
ium and cell extracts compatible with inhibition of
expression. In view of the continued interest in targeting
PI 3-kinases in cancer (Yap et al. 2008; Fruman and
Rommel 2014) we therefore suggest that MMP-7 may
have potential both as downstream target of this pathway
in BE/EAC and as a biomarker of it. Nevertheless, care is
required in interpretation of the data not least because
some other related cells lines including for example FLO-
1 cells and the gastroesophageal junction cancer cell line
OE19 express MMP-7 either weakly or not at all (Keld
et al. 2010).
Several MMPs have previously been shown to be
increased in esophageal adenocarcinoma, including
MMP-1 (Grimm et al. 2010), MMP-9 and MMP-13
(Davelaar et al. 2015). Increased MMP activity detected
by MMPsense680 activity occurs in the progression to
EAC; two of the main activators of this substrate are
MMP-9 and MMP-13, the former is low in relative abun-
dance in metaplasia and increases in EAC, the latter is
higher in metaplasia than EAC indicating potential
switches in MMP expression in progression (Davelaar
et al. 2015). The present study indicates that MMP-7
should also be included as a functionally relevant MMP
that is implicated in the progression to EAC. Since
MMP-7 stimulates esophageal myofibroblast migration
and invasion and was partly responsible for the effect of
OE33 cell CM in stimulating myofibroblast responses we
suggest that the increased MMP-7 in BE and EAC con-
tributes to a microenvironment favoring tumor invasion
both by degradation of extracellular matrix and by
remodeling stromal cell distribution by control of myofi-
broblast motility (Fig 8). In this sense, there may be par-
allels between the role of MMP-7 in shaping the
PI 3-kinase PI 3-kinase PI 3-kinase
Barre’s
metaplasia
Barre’s
dysplasia
Esophageal
adenocarcinoma
Squamous
epithelium
proMMP-7 proMMP-7 proMMP-7proMMP-7
MMP-7 MMP-7 MMP-7
acvaon
proMMP-7
degradaon
migraon/invasion
Figure 8. Schematic representation of the role of MMP-7 in the progression from Barrett’s esophagus to esophageal adenocarcinoma.
Differences in font size and line thickness indicate the magnitude of effects. It is suggested that there is progressively increased expression of
proMMP-7 in progress to EAC at least in part due to activation of PI 3-kinase, that following secretion conversion of proMMP-7 to MMP-7
activates stromal cells stimulating myofibroblast migration and invasion and remodeling of the cancer cell microenvironment.
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esophageal microenvironment and that in the stomach
and colon where there is already evidence that MMP-7
stimulates stromal cell function via cleavage of insulin-like
growth factor binding proteins (IGFBPs) leading to
increased bioavailability of IGF-I and –II (Hemers et al.
2005; McCaig et al. 2006).
In conclusion, the present data support the concept
that MMP-7 has potential both as a target that drives
EAC progression and as a biomarker of it. Functionally,
the role of MMP-7 in promoting invasion that has previ-
ously been recognized in other gastrointestinal cancers
(Adachi et al. 2009) is also likely to apply to EAC. In
addition, the unexpected expression of MMP-7 in myofi-
broblasts associated with invasive EAC may be useful as a
novel dimension in histopathology even though the func-
tional significance in this case remains to be determined.
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